#URGN
LightNews LightNews
merlintrader.bsky.social
#$URGN reports Q3 earnings today before the open.

Consensus: EPS $0.05, revenue $90M.
Call 10:00 AM ET: investors.urogen.com

Explore the chart on JustCharts:
justcharts.merlintrader.com#URGN
URGN hub: www.merlintrader.com/urogen-pharm...
November 4, 2026 at 12:28 PM
merlintrader.bsky.social
#$URGN — UroGen Q3: ZUSDURI revenue $68.0M, up 35% q/q; total revenue $89.0M.
Net loss narrowed to $1.5M; cash and securities $90.5M.

URGN Stock Hub: UroGen Pharma News, ZUSDURI Growth and UGN-103 Review
www.merlintrader.com/urogen-pharm...
November 4, 2026 at 4:38 PM
fundspec.bsky.social
UroGen Pharma $URGN reported Q3 2026 EPS of -$0.03, missing the $0.09 estimate by 133.3%. Revenue of $89.0M missed the $89.3M estimate by 0.3%.

https://fundspec.ai/s/URGN/earnings
Get a push the moment an analyst moves a price target.
November 4, 2026 at 1:15 PM
quant-hub.bsky.social
🚨 $URGN
On November 4, 2026, UroGen Pharma Ltd. announced its financial results for the quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be dee...
SEC Filing: URGN
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 1:08 PM
merlintrader.bsky.social
UroGen #$URGN will present at the Guggenheim conference in Boston.

The presentation is set for Nov 10 at 11:30 a.m. ET.

Shares closed at $34.36 Mon: below SMA50, above SMA200, RSI 38.

Hub: www.merlintrader.com/urogen-pharm...

Not investment advice.
URGN Stock: UroGen Pharma News, ZUSDURI & UGN-103
UroGen Pharma stock news: ZUSDURI sales, cash collections, UGN-103 regulatory review and the financing obligations behind its commercial growth.
www.merlintrader.com
November 3, 2026 at 5:11 PM
stocktitan.net
#URGN UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

https://www.stocktitan.net/news/URGN/uro-gen-reports-68-0-million-of-zusduri-revenue-and-provides-third-4agfeuq66l53.html?utm_source=stocktitan-bluesky&utm_medium=social
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
November 4, 2026 at 1:00 PM
stocktitan.net
#URGN UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference

https://www.stocktitan.net/news/URGN/uro-gen-pharma-to-present-at-the-guggenheim-securities-3rd-annual-63hm3md4g955.html?utm_source=stocktitan-bluesky&utm_medium=social
UroGen's conference webcast will be available, with a replay for about 90 days.
Management will take part in a fireside chat and one-on-one investor meetings in Boston on Nov. 10 at 11:30 a.m. ET; the conference runs Nov. 9–11.
www.stocktitan.net
November 3, 2026 at 1:00 PM
elixstocksdata.bsky.social
UroGen Pharma ($URGN) – 13G holder update

• Holder: BlackRock
• Stake: now 6.3% (about $103M)
• SEC Filing: Schedule 13G/A
• Filing Date: October 27, 2026

📊 Track ownership filings at www.elixstocks.com

Educational purposes only. Not investment advice.

#Investing #Stocks #13G #ElixStocks
BlackRock, Inc.: 6.3% of UroGen Pharma ($URGN)
Schedule 13G/A filed Oct 27. Who filed, the stake, and how it changed.
elixstocks.com
October 29, 2026 at 12:08 AM
merlintrader.bsky.social
#$URGN Q3 2026 results call: Wed Nov 4, 10:00 a.m. ET. Close $33.48 (Oct 29), RSI 29 (oversold), 20d range $32.96-$43.54.
investors.urogen.com/events/event...
www.merlintrader.com/urogen-pharm...
October 30, 2026 at 2:00 PM
merlintrader.bsky.social
#$URGN Q3 2026 results call: Wed Nov 4, 10:00 a.m. ET. Close $33.48 (Oct 29), RSI 29 (oversold), 20d range $32.96-$43.54.
investors.urogen.com/events/event...
www.merlintrader.com/urogen-pharm...
October 30, 2026 at 2:00 PM
merlintrader.bsky.social
$URGN Oct 28, 2026: UroGen announced publication of the final five-year Olympus follow-up of JELMYTO in low-grade upper tract urothelial cancer: among the 41 patients with a complete response, median duration of response was 47.8 months.

https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/
UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash?
UroGen: ZUSDURI adoption, UGN-103 review, cash use, debt and dilution. Dated evidence and scenarios behind the commercial growth of $URGN.
www.merlintrader.com
October 28, 2026 at 3:36 PM
merlintrader.bsky.social
$URGN Oct 28, 2026: UroGen announced publication of the final five-year Olympus follow-up of JELMYTO in low-grade upper tract urothelial cancer: among the 41 patients with a complete response, median duration of response was 47.8 months.

https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/
UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash?
UroGen: ZUSDURI adoption, UGN-103 review, cash use, debt and dilution. Dated evidence and scenarios behind the commercial growth of $URGN.
www.merlintrader.com
October 28, 2026 at 3:36 PM
stocktitan.net
#URGN UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Gr…

https://www.stocktitan.net/news/URGN/uro-gen-s-final-results-from-olympus-five-year-follow-up-study-zbrch5h0bjvi.html?utm_source=stocktitan-bluesky&utm_medium=social
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
UroGen Pharma (Nasdaq: URGN) announced publication of final Olympus five-year follow-up results evaluating JELMYTO response durability in adults with low-grade upper tract urothelial cancer.Among 41 patients who achieved a complete response after initial treatment, median response duration was 47.8 months, with median follow-up of 28.1 months (95% confidence interval: 13.1–60.1). Twenty patients entered long-term follow-up, with median follow-up of 53.3 months (95% confidence interval: 27.9–72.8). In that group, median response duration could not be estimated because too few events occurred; its 95% confidence interval was 43.5 months to not estimable. As of March 2025, 75% (15/20) remained event-free, with no progression to high-grade disease observed. The results appeared in Therapeutic Advances in Urology.
www.stocktitan.net
October 28, 2026 at 12:00 PM
merlintrader.bsky.social
FDA accepted UroGen's UGN-103 NDA; PDUFA target action date June 14, 2027. $URGN

https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/
UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash?
UroGen: ZUSDURI adoption, UGN-103 review, cash use, debt and dilution. Dated evidence and scenarios behind the commercial growth of $URGN.
www.merlintrader.com
October 19, 2026 at 5:32 PM
stocktitan.net
#URGN UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Re…

https://www.stocktitan.net/news/URGN/uro-gen-announces-fda-acceptance-of-the-new-drug-application-for-ugn-ogs2bo7m7vt8.html?utm_source=stocktitan-bluesky&utm_medium=social
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 19, 2026 at 12:00 PM
$FTNT-1 $HUT-1 $BNY-1 $PRIM-1 $MU-1 $EWJ-1 $KO-1 $BSX-1 $SBLK-1 $VXX-1 $PDD-1 $AVGO-1 $WMT-1 $SMH-1 $PSQ-1 $BORR-1 $SOC-1 $LOPE-1 $TALO-1 $PLMR-1 $RIOT-1 $XTL-1 $CHKP-1 $APLD-1 $CAE-1 $CPB-1 $ASTS-1 $FAST-1 $NIQ-1 $AIA-1 $CVE-1 $AAOI-1 $NVDL-1 $URGN-1 $IVV-1 $GEHC-1
October 19, 2026 at 8:12 PM
philsan.bsky.social
Super Mario 64 on #AtariJaguar console www.youtube.com/watch?v=URGn... #atari
Proof: Super Mario 64 on real Atari Jaguar Hardware
The footage looks choppy because the CRT's refresh rate doesn't perfectly sync with the phone camera's frame rate and shutter speed. A better capture from emulator: https://youtu.be/pBJxz8FlSfE
www.youtube.com
October 15, 2026 at 4:33 PM
tradeinsight.info
#URGN CFO Chris Degnan chopped 33% of his stake for $81K. Meanwhile, #FEAM CEO Paul Weibel picked up $25K, expanding his holdings by 20%.
October 10, 2026 at 1:56 PM
quant-hub.bsky.social
🚨 $URGN
Degnan Chris (Chief Financial Officer) sold 2,202 shares at an average price of $36.6900 per common share. (Date: 2026-10-08)
SEC Filing: URGN
Click to view the official SEC document.
www.sec.gov
October 9, 2026 at 4:57 PM
quant-hub.bsky.social
🚨 $URGN
Christopher Degnan, a Officer, filed a notice of intent to sell 2,202 shares of common stock, valued at approximately $89,621.40, on 10/08/2026.
SEC Filing: URGN
Click to view the official SEC document.
www.sec.gov
October 9, 2026 at 10:24 AM
merlintrader.bsky.social
Latest company news, September 4: UroGen announced inducement grants for new employees, after its IntraGel collaboration on August 20.
UroGen (#$URGN): Can ZUSDURI Growth Turn Into Cash?
www.merlintrader.com/urogen-pharm...
UroGen ($URGN): Can ZUSDURI Growth Turn Into Cash?
UroGen: ZUSDURI adoption, UGN-103 review, cash use, debt and dilution. Dated evidence and scenarios behind the commercial growth of $URGN.
www.merlintrader.com
October 7, 2026 at 2:57 PM
merlintrader.bsky.social
UroGen (#$URGN): UGN-103 NDA Submitted, Phase 3 Start in H2

Free Biotech Catalyst Calendar on Merlintrader.

www.merlintrader.com/urogen-pharm...
September 23, 2026 at 1:31 PM
nepaliwikipedia.bsky.social
'पर्वत सुवेदी'ले नेपाली विकिपिडियामा 'लुम्बिनी अञ्चल' https://w.wiki/URGN सम्पादन गर्नुभयो ।
मितिः २०८३ भदौ २६ गते, शुक्रबार
समयः रातको ०९:३४ बजे
#NepaliWikipedia
September 11, 2026 at 3:50 PM
quant-hub.bsky.social
🚨 $URGN
Robinson James A. Jr. (Insider) reported special transactions (Non-P/S).
SEC Filing: URGN
Click to view the official SEC document.
www.sec.gov
August 28, 2026 at 8:02 PM
formdelta.bsky.social
🔴 #URGN — Schoenberg Mark, Chief Medical Officer
SOLD: 60,677 shares @ $47.05
Total: $2.9M
Filed Aug 19, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/URGN

#InsiderTrading #URGN #StockMarket
FormDelta — Insider Trading Alerts
Schoenberg Mark just sold $2.9M in URGN. Track all SEC Form 4 insider trades in real-time.
www.formdelta.com
August 24, 2026 at 9:07 PM